Fusogenic Lipid Nanoparticles for Cell-Specific Therapeutic Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current systems for targeting and eliminating senescent cells in mammals suffer from substantial systemic toxicity, inadequate targeting, and lack of safety features, limiting their therapeutic efficacy in treating cancers and slowing aging effects.
Innovation Solution
The use of expression constructs and systems that exploit unique transcription regulatory machinery in target cells, such as senescent cells, to induce the expression of therapeutic proteins like Casp3, Casp8, Casp9, BAX, DFF40, HSV-TK, and cytosine deaminase, which reduce or eliminate target cell growth and survival without the need for specific delivery, utilizing fusogenic lipid nanoparticles and optional targeting moieties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current systems for targeting and eliminating senescent cells are used, then therapeutic efficacy is limited, but systemic toxicity increases
Solution Approach 1:
The patent applies local quality by making the therapeutic system selectively active only in target cells through cell-specific promoters that drive expression of pro-apoptotic proteins only in senescent or cancer cells, not in healthy cells. This localized expression reduces systemic toxicity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent uses fusogenic lipid nanoparticles as intermediaries to deliver nucleic acid sequences encoding pro-apoptotic proteins to target cells. These nanoparticles facilitate targeted delivery and controlled release, reducing off-target effects and systemic toxicity while improving therapeutic efficacy.
2Reliability
If current systems for targeting and eliminating senescent cells are used, then therapeutic efficacy is limited, but inadequate targeting occurs
Solution Approach 1:
The patent employs cell-specific promoters that are selectively active in target cells (senescent or cancer cells) to drive expression of therapeutic proteins only in those cells. This ensures precise targeting at the molecular level, improving both targeting accuracy and therapeutic efficacy.
Solution Approach 2:
The patent uses inducible promoter systems that allow dynamic control of pro-apoptotic protein expression. The expression can be turned on or off in response to specific conditions or signals, enabling precise temporal and spatial control of therapeutic action in target cells.
3Reliability
If current systems for targeting and eliminating senescent cells are used, then safety features are lacking, but toxicity increases
Solution Approach 1:
The patent ensures safety by confining the expression of pro-apoptotic proteins to specific target cells through cell-specific promoters. Healthy cells do not express these proteins, eliminating off-target toxicity and providing inherent safety through selective cellular targeting.
Solution Approach 2:
The patent employs safety mechanisms where the system itself controls its activation through cell-specific promoter recognition. Only cells with the appropriate transcriptional machinery and promoter recognition will express the therapeutic proteins, providing self-regulating safety without external control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves high target cell specificity and safety by leveraging intracellular functionality unique to target cells, reducing or eliminating senescent cells through apoptosis or other cellular processes, while minimizing toxicity and immunogenicity.
Implementation Method 1
a lipid nanoparticle including one or more lipid(s) and one or more fusogenic protein(s)
Data Source
AI summary
Provided nucleic acid-based expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, within a target cell, including a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell. Also provided are formulations and systems, including fusogenic lipid nanoparticle (LNP) formulations and systems, for the delivery of nucleic acid-based expression constructs as well as methods for making and using such nucleic acid-based expression constructs, formulations, and systems for reducing, preventing, and/or eliminating the growth and/or survival of a cell, such as a senescent cell and/or a cancer cell, which is associated with aging, disease, or other condition as well as methods for the treatment of aging, disease, or other conditions by the in vivo administration of a formulation, such as a fusogenic LPN formulation, comprising an expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, in a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell.